In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, CureVac N.V’s stock clocked out at $2.77, up 4.14% from its previous closing price of $2.66. In other words, the price has increased by $4.14 from its previous closing price. On the day, 0.54 million shares were traded. CVAC stock price reached its highest trading level at $2.815 during the session, while it also had its lowest trading level at $2.65.
Ratios:
To gain a deeper understanding of CVAC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.70. For the most recent quarter (mrq), Quick Ratio is recorded 6.19 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on April 25, 2024, Downgraded its rating to Market Perform and sets its target price to $4 from $12 previously.
On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.
UBS Upgraded its Neutral to Buy on January 19, 2023, whereas the target price for the stock was revised from $8 to $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 27 ’24 when Pierre Kemula bought 55 shares for $3.08 per share.
Pierre Kemula bought 34,000 shares of CVAC for $105,400 on Sep 25 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 621416256 and an Enterprise Value of 457869824. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.08 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 6.952 whereas that against EBITDA is -1.694.
Stock Price History:
Over the past 52 weeks, CVAC has reached a high of $6.30, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is -3.19%, while the 200-Day Moving Average is calculated to be -13.12%.
Shares Statistics:
It appears that CVAC traded 472.09K shares on average per day over the past three months and 658950 shares per day over the past ten days. A total of 223.99M shares are outstanding, with a floating share count of 93.63M. Insiders hold about 58.26% of the company’s shares, while institutions hold 5.18% stake in the company. Shares short for CVAC as of 1730332800 were 4560158 with a Short Ratio of 9.66, compared to 1727654400 on 4785625. Therefore, it implies a Short% of Shares Outstanding of 4560158 and a Short% of Float of 11.3800004.
